Continuous Glucose Monitoring for Postkidney Transplantation in Patients With Pre-existing Type 2 Diabetes
Authors' conclusion
These findings may assist with better insulin dosing for programs that have similar patient demographics and prednisone taper.
Study context
- Population
- Kidney transplant recipients with pre-existing T2D on insulin therapy, during prednisone taper
- Outcome
- Glucometrics achieved with a CGM-based insulin titration protocol
Methodological detailssingle-group, continuous glucose monitor (CGM) metrics used to adjust insulin dose for 3 months; data up to 6 months included
- Single-group
- CGM metrics used to adjust insulin dose for 3 months; data up to 6 months included
Main finding
As reported in the abstract
Time in range · baseline, 3 and 6 months
TIR at baseline
44.2%
TIR at 3 months (P = .005)
60.8%
TIR at 6 months (P < .001)
72.9%
Further findings
Average glucose · baseline, 3 and 6 months
mg/dL
- Baseline
- 194.7
- 3 months
- 160.6
- 6 months (P < .001)
- 148.0
Estimated mean total insulin dose per kg body weight · baseline, 3 and 6 months
Units/kg
- Baseline
- 0.48
- 3 months
- 0.66
- 6 months
- 0.56
Safety
TBR 54-69 mg/dL · baseline, 3 and 6 months
- Baseline
- 0.3%
- 3 months (P = .11)
- 0.4%
- 6 months (P = .036)
- 0.6%
TBR <54 mg/dL · baseline, 3 and 6 months
- Baseline
- 0%
- No significant increase at 3 and 6 months
Original publication
Continuous Glucose Monitoring for Postkidney Transplantation in Patients With Pre-existing Type 2 Diabetes. Endocr Pract. Published 19 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →